REG - Novacyt S.A. - Strategy update & notice of investor presentation

Novacyt SAAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251022:nRSV2682Ea&default-theme=true

RNS Number : 2682E  Novacyt S.A.  22 October 2025

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Strategy update and notice of investor presentation

 

Paris, France, and Manchester, UK - 22 October 2025 - Novacyt S.A. (EURONEXT
GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company
with a broad portfolio of integrated technologies and services, announces it
will issue an investor presentation today via the Investor Meet Company
platform, detailing the Company's growth plan, providing FY25 outlook and will
set out its strategic goals, as detailed below.

 

FY25 outlook

Novacyt expects to see a slight increase in H2 2025 revenues vs H1 2025,
driven primarily by increased instrument sales, with new orders received from
the recently launched LightBench® Discover instrument. The Group expects to
report an improvement in EBITDA loss for 2025 compared to the loss reported in
FY24 of £9.1m which will be supported by an improved gross margin
contribution. Cash outflow is also expected to improve in H2 2025 and will be
lower than the H1 2025 cash outflow of £6.8m, largely as a result of
completing the site consolidation and restructuring work.

 

Organic financial goals

Novacyt has set out and committed to the following three organic KPIs, clearly
defined below:

 

1)    To deliver double digit revenue growth year-on-year (from FY26)

2)    To deliver a gross margin across the Group of over 60% each year (H1
FY25 66%)

3)    To achieve EBITDA profitability based on the organic growth plans
supported by the Company's balance sheet strength as soon as possible

 

Growth strategy

Following a period of restructuring, reducing the cost base and rightsizing
the Group's operational footprint, the business is now derisked with a strong
core business and foundations for growth. Novacyt has an established customer
base in key markets and a robust commercialisation strategy to drive the
business forward with the ability to rapidly pivot and leverage the Group's
core capabilities to meet emerging market needs.

 

In 2024, the Company agreed to invest up to £2m per year from 2025-2027 to
accelerate bringing new products to market. Novacyt continues to execute this
strategy with product launches such as LightBench® Discover in July 2025, to
support PacBio's labs using long read sequencers and the APAC focused NIPT
solution which was launched in Q4 2025 to meet the changing needs of the APAC
market. Through a mixed model strategy of licensing external technologies and
building the Group's own products in-house, alongside strong partnerships and
collaborations with blue chip partners, Novacyt has created a solid foundation
from which it can deliver top line growth to support it reaching EBITDA
profitability.

 

Investor presentation

The investor presentation will be issued on Wednesday 22 October at 7.00am BST
and include presentations from Lyn Rees, Chief Executive Officer, and Steve
Gibson, Chief Financial Officer, who will talk through the interim results for
the six months ended 30 June, the organic financial targets set out by the
Company above and how the Group is well positioned for growth. The
presentation will also feature contributions from both Dr. Jo Mason, Chief
Scientific Officer, and Maria Watters, Chief Commercial Officer, who will
discuss the New Product Introduction strategy of the Group and
Commercialisation.

 

Investors can sign up to Investor Meet Company for free and register here
(https://www.investormeetcompany.com/novacyt-sa/register-investor) .

 

The presentation will be made available on the Company's website here -

https://novacyt.com/investors/presentations/
(https://novacyt.com/investors/presentations/)

 

Shareholders and interested parties can sign up to receive the latest
Company's announcements and updates by emailing: novacyt@walbrookpr.com.

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                             +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Singer Capital Markets (Joint Broker)                                                                     +44 (0) 20 7496 3000
 Tom Salvesen / Phil Davies / James Fischer / Samed Ethemi

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com

 Paul McManus / Lianne Applegarth                                        +44 (0)7980 541 893 / +44 (0)7584 391 303

 Alice Woodings                                                           +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel

 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·    Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                      whole exome sequencing (WES)

 

Novacyt is headquartered in Le Vésinet in France with offices in the UK
(Manchester), Singapore, the US and Canada and has a commercial presence in
over 65 countries. The Company is listed on the London Stock Exchange's AIM
market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDPKDBNPBDDCKB



            Copyright 2019 Regulatory News Service, all rights reserved